CARDIOPLEGIC IN PLASTIC CONTAINER (calcium chloride)
Ringer’s Injection is indicated for use in adult and pediatric patients as a source of water and electrolytes. It is used to maintain or restore fluid volume and provide essential ions necessary for physiological homeostasis.
How CARDIOPLEGIC IN PLASTIC CONTAINER Works
Ringer’s Injection provides essential electrolytes to regulate fluid distribution and acid-base balance. Sodium manages osmotic pressure and water distribution, while chloride assists in maintaining acid-base equilibrium. Potassium acts as the primary intracellular cation, critical for nerve conduction, muscle contraction (particularly cardiac), carbohydrate utilization, and protein synthesis. Calcium is provided to support blood coagulation, normal cardiac function, and the regulation of neuromuscular irritability.
Details
- Status
- Prescription
- First Approved
- 2000-04-21
- Routes
- PERFUSION, CARDIAC
- Dosage Forms
- SOLUTION
Companies
CARDIOPLEGIC IN PLASTIC CONTAINER Approval History
What CARDIOPLEGIC IN PLASTIC CONTAINER Treats
2 indicationsCARDIOPLEGIC IN PLASTIC CONTAINER is approved for 2 conditions since its original approval in 2000. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Water deficiency
- Electrolyte deficiency
Drugs Similar to CARDIOPLEGIC IN PLASTIC CONTAINER
3 of 19FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
7 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07550413 | 20042026 | Ph 2 | not yet recruiting | Role of Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Section |
| NCT03772990 ICARUS | 21/2019 | Ph 4 | completed | Calcium Administration in Cardiac Surgery |
| NCT05027048 CALBLOC results posted | 62206 MRTG-02-15-2022-Ansari, YIG-2020 | Ph 3 | completed | Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery |
| NCT04153435 COCA results posted | 00002 2019-003387-46 | Ph 2 | completed | Calcium for Out-of-Hospital Cardiac Arrest |
| NCT03867383 results posted | 43076 | Ph 1, Ph 2 | completed | Calcium Chloride for Prevention of Uterine Atony During Cesarean |
| NCT01941914 | AA1310 | Ph 1 | completed | Calcium Electroporation for the Treatment of Keloids |
| NCT00955266 results posted | 2009-P-000052 | Ph 4 | terminated | A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CARDIOPLEGIC IN PLASTIC CONTAINER FDA Label Details
Indications & Usage
CARDIOPLEGIC IN PLASTIC CONTAINER is indicated for the treatment of Water deficiency; Electrolyte deficiency.
Track CARDIOPLEGIC IN PLASTIC CONTAINER with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.